Patient Diversity

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy

Regulator cited flaws in RP1’s pivotal IGNYTE trial design and patient diversity, prompting Replimune to request a high-priority FDA meeting within 30 days.